Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Dosage  





2 Effects  





3 Pharmacology  



3.1  Pharmacodynamics  







4 Clinical trials  





5 Legal status  



5.1  Finland  





5.2  Germany  





5.3  Sweden  





5.4  United States  



5.4.1  Florida  









6 References  





7 External links  














4-HO-DiPT






Deutsch
Français
Македонски
Polski
Српски / srpski
Srpskohrvatski / српскохрватски
Suomi

 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 




In other projects  



Wikimedia Commons
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


4-HO-DiPT
Clinical data
Routes of
administration
Oral
Legal status
Legal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
  • US: Unscheduled
  • Pharmacokinetic data
    Elimination half-life1-2 hrs
    Identifiers
    • 3-[2-(diisopropylamino)ethyl]-1H-indol-4-ol

    CAS Number
  • HCl: 63065-90-7 checkY
  • ChemSpider
    UNII
  • HCl: KE76PMQ2P3 checkY
  • CompTox Dashboard (EPA)
    ECHA InfoCard100.214.853 Edit this at Wikidata
    Chemical and physical data
    FormulaC16H24N2O
    Molar mass260.381 g·mol−1
    3D model (JSmol)
    • CC(C)N(CCc1c[nH]c2cccc(O)c12)C(C)C

    • InChI=1S/C16H24N2O/c1-11(2)18(12(3)4)9-8-13-10-17-14-6-5-7-15(19)16(13)14/h5-7,10-12,17,19H,8-9H2,1-4H3 checkY

    • Key:KBRYKXCBGISXQV-UHFFFAOYSA-N checkY

     ☒NcheckY (what is this?)  (verify)
    4-HO-DiPT Powder
    4-HO-DiPT Powder

    4-Hydroxy-N,N-diisopropyltryptamine (4-HO-DiPTorIprocin) is a synthetic psychedelic drug. It is a higher homologueofpsilocin, 4-HO-DET, and is a positional isomer of 4-HO-DPT and has a tryptamine molecular sub-structure.

    Dosage[edit]

    4-HO-DiPT is orally active at around 3 mg and above, and its effects last for 2–3 hours.[1] Higher doses such as those above 30 mgs can increase the duration of the effects significantly.

    Effects[edit]

    The effects of 4-HO-DiPT are broadly comparable to those of other serotonergic psychedelics such as LSD and psilocin, but they are distinguished by their relative brevity. Shulgin "doubt[s] that there is another psychedelic drug, anywhere, that can match this one for speed, for intensity, for brevity, and sensitivity to dose, at least one that is active orally." An idiosyncratic effect of the drug, also noted by Shulgin, is its tendency to induce tremors.[2][3][4]

    Some users have reported a minor audio distortion with lower dosages. Higher dosages increase the polarity of the distortion. It is defined as being slightly lower in pitch and creating several different effects, such as pitch bend, volume distortion, and rate distortion. As with most DiPT psychedelics, music can become more dissonant and less harmonious. Users have also reported a visual distortion widely comparable to the hallucinogen LSD.

    Pharmacology[edit]

    Pharmacodynamics[edit]

    Binding Sites Binding Affinity Ki (μM) Action [5]
    5-HT1A 5.7 ???
    5-HT2A 0.728 partial agonist
    5-HT2C 2.8 ???
    D1 >25 ???
    D2 >25 ???
    D3 >25 ???
    α1A >12 ???
    α2A 15 ???
    TAAR1 >15 ???
    H1 9.8 ???
    SERT 1.8 inhibitor
    DAT >26 inhibitor
    NET 11 inhibitor

    Clinical trials[edit]

    FT-104, a prodrug to 4-HO-DiPT, has entered double blind, randomized, placebo controlled, phase 1 clinical trials in healthy volunteers at the Royal Adelaide Hospital in Australia for the treatment of postpartum depression and treatment-resistant depression. [6][7][8]

    FT-104 [1]

    Legal status[edit]

    Finland[edit]

    Scheduled in government decree on psychoactive substances banned from the consumer market.[9]

    Germany[edit]

    Scheduled in New Psychoactive Substances Act (NpSG). Use of covered substances is permitted only for industrial and scientific purposes.

    Sweden[edit]

    Sveriges riksdags health ministry Statens folkhälsoinstitut classified 4-HO-DiPT as "health hazard" under the act Lagen om förbud mot vissa hälsofarliga varor (translated Act on the Prohibition of Certain Goods Dangerous to Health) as of Mar 1, 2005, in their regulation SFS 2005:26 listed as 4-hydroxi-N,N-diisopropyltryptamin (4-HO-DIPT), making it illegal to sell or possess.[10]

    United States[edit]

    4-HO-DiPT is not scheduled at the federal level in the United States,[11] but it is possible that it could be considered an analog of 5-MeO-DiPT, in which case purchase, sale, or possession could be prosecuted under the Federal Analog Act.

    Florida[edit]

    "4-Hydroxy-N,N-diisopropyltryptamine" is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess in Florida.[12]

    References[edit]

    1. ^ "Erowid 4-HO-DiPT Vault : Dosage". www.erowid.org. Retrieved 8 April 2023.
  • ^ Shulgin, Alexander; Shulgin, Ann (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252.
  • ^ "4-Hydroxy-DIPT". Erowid.
  • ^ "Tihkal 4-HO-DIPT entry".
  • ^ Rickli A, Moning OD, Hoener MC, Liechti ME (August 2016). "Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens" (PDF). European Neuropsychopharmacology. 26 (8): 1327–37. doi:10.1016/j.euroneuro.2016.05.001. PMID 27216487. S2CID 6685927.
  • ^ "Field Trip Announces First Dosings in Phase I Clinical Study of FT-104" (Press release). 21 July 2022.
  • ^ "An Inside Look into Field Trip's Next-Generation Psychedelic, FT-104". 11 August 2022.
  • ^ "WIPO - Search International and National Patent Collections". patentscope.wipo.int. Retrieved 8 April 2023.
  • ^ "FINLEX ® - Säädökset alkuperäisinä: Valtioneuvoston asetus kuluttajamarkkinoilta… 1130/2014". www.finlex.fi. Retrieved 8 April 2023.
  • ^ "Svensk författningssamling" [Swedish Code of Statutes] (PDF) (in Swedish). Archived from the original (PDF) on 29 September 2013. Retrieved 25 September 2013.
  • ^ "21 CFR — SCHEDULES OF CONTROLLED SUBSTANCES §1308.11 Schedule I." Archived from the original on 27 August 2009. Retrieved 17 December 2014.
  • ^ "Statutes & Constitution :View Statutes : Online Sunshine". leg.state.fl.us. Retrieved 8 April 2023.
  • External links[edit]


    Retrieved from "https://en.wikipedia.org/w/index.php?title=4-HO-DiPT&oldid=1200749614"

    Categories: 
    Phenols
    Psychedelic tryptamines
    Designer drugs
    Diisopropylamino compounds
    Tertiary amines
    Hidden categories: 
    CS1 Swedish-language sources (sv)
    Articles with short description
    Short description matches Wikidata
    Use dmy dates from April 2023
    ECHA InfoCard ID from Wikidata
    Articles without EBI source
    Chemical pages without DrugBank identifier
    Articles without KEGG source
    Multiple chemicals in Infobox drug
    Chemicals using indexlabels
    Chemical articles with multiple CAS registry numbers
    Drugs missing an ATC code
    Drugboxes which contain changes to verified fields
    Commons category link from Wikidata
     



    This page was last edited on 30 January 2024, at 05:01 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki